Document is current
Any future updates will be listed below
-
Authors
Jachimowicz, Ron D. https://orcid.org/0000-0001-9522-7061
Klapper, Wolfram https://orcid.org/0000-0001-7208-4117
Glehr, Gunther
Müller, Horst
Haverkamp, Heinz https://orcid.org/0000-0001-6895-4132
Thorns, Christoph
Hansmann, Martin Leo
Möller, Peter
Stein, Harald
Rehberg, Thorsten
von Tresckow, Bastian
Reinhardt, H. C.
Borchmann, Peter
Chan, Fong Chun
Spang, Rainer
Scott, David W.
Engert, Andreas
Steidl, Christian https://orcid.org/0000-0001-9842-9750
Altenbuchinger, Michael
Rosenwald, Andreas
- License Information
-
More Information
Article History
Received: 29 January 2021
Revised: 23 May 2021
Accepted: 27 May 2021
First Online: 10 June 2021
Compliance with ethical standards
:
: Employment or Leadership Position: None; Consultant or Advisory Role: AE, Takeda, BMS; HCR, Abbvie, AstraZeneca; BvT, Amgen, Pfizer, Takeda, MSD; WK, Takeda; CS Seattle Genetics, Curis Inc., Roche, AbbVie, AstraZeneca, Juno Therapeutics, Bayer; Stock Ownership: None; Honoraria: AE, Takeda, BMS, WK, Takeda; BvT, Roche, Takeda, MSD; Research Funding: AE, Takeda, BMS, Affimed; HCR, Gilead Sciences; BvT, Novartis, MSD, Takeda; WK, Takeda, Amgen, Regeneron, Roche; CS. Bristol-Myers Squibb, Epizyme and Trillium Therapeutics Inc.; Expert Testimony: None; Other Remuneration: None
